Back to Search Start Over

MicroRNA-dependent inhibition of WEE1 controls cancer stem-like characteristics and malignant behavior in ovarian cancer

Authors :
Jin Gu Cho
Sung-wook Kim
Aram Lee
Ha-neul Jeong
Eunsik Yun
Jihea Choi
Su Jin Jeong
Woochul Chang
Sumin Oh
Kyung Hyun Yoo
Jung Bok Lee
Sukjoon Yoon
Myeong-Sok Lee
Jong Hoon Park
Min Hyung Jung
So-Woon Kim
Ki Hyung Kim
Dong Soo Suh
Kyung Un Choi
Jungmin Choi
Jongmin Kim
Byung Su Kwon
Source :
Molecular Therapy - Nucleic Acids. 29:803-822
Publication Year :
2022
Publisher :
Elsevier BV, 2022.

Abstract

Cancer stem-like cells (CSCs) have been suggested to be responsible for chemoresistance and tumor recurrence owing to their self-renewal capacity and differentiation potential. Although WEE1 is a strong candidate target for anticancer therapies, its role in ovarian CSCs is yet to be elucidated. Here, we show that WEE1 plays a key role in regulating CSC properties and tumor resistance to carboplatin via a microRNA-dependent mechanism. We found that WEE1 expression is upregulated in ovarian cancer spheroids because of the decreased expression of miR-424 and miR-503, which directly target WEE1. The overexpression of miR-424/503 suppressed CSC activity by inhibiting WEE1 expression, but this effect was reversed on the restoration of WEE1 expression. Furthermore, we demonstrated that NANOG modulates the miR-424/503-WEE1 axis that regulates the properties of CSCs. We also demonstrated the pharmacological restoration of the NANOG-miR-424/503-WEE1 axis and attenuation of ovarian CSC characteristics in response to atorvastatin treatment. Lastly, miR-424/503-mediated WEE1 inhibition re-sensitized chemoresistant ovarian cancer cells to carboplatin. Additionally, combined treatment with atorvastatin and carboplatin synergistically reduced tumor growth, chemoresistance, and peritoneal seeding in the intraperitoneal mouse models of ovarian cancer. We identified a novel NANOG-miR-424/503-WEE1 pathway for regulating ovarian CSCs, which has potential therapeutic utility in ovarian cancer treatment.

Subjects

Subjects :
Drug Discovery
Molecular Medicine

Details

ISSN :
21622531
Volume :
29
Database :
OpenAIRE
Journal :
Molecular Therapy - Nucleic Acids
Accession number :
edsair.doi.dedup.....a04964f9dcd2d8d5dab92291159050c7